Stem Cell Company Investigating Treatment for COPD

By: Tomas Ronolski - AllPennyStocks.com News

Monday, May 9, 2022

COPD drastically affects the lives of many people, and represents a $10 billion dollar market. This company is seeking to use stem cells to investigate future therapeutics to treat the disease.

Focusing on immune modulation for the treatment of several specific diseases, Therapeutic Solutions International, Inc. (OTC: TSOI) announced today filing of an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA). Per the company’s press release, TSOI is seeking permission to treat 10 patients with advanced COPD using its universal donor adult stem cell product termed “JadiCell™”.

JadiCell is also being investigated as a treatment for COVID-19, and a Phase III clinical trial has been initiated, as well as for Chronic Traumatic Encephalopathy (CTE), for which the Company has been granted an IND by the U.S. FDA.

Shares were trading down on Monday at $0.00065.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.